I-MAB-SPONSORED ADR (IMAB) Stock Price & Overview
NASDAQ:IMAB • US44975P1030
Current stock price
The current stock price of IMAB is 4.63 USD. Today IMAB is down by -0.22%. In the past month the price increased by 19.95%. In the past year, price increased by 332.71%.
IMAB Key Statistics
- Market Cap
- 533.682M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
IMAB Stock Performance
IMAB Stock Chart
IMAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMAB. When comparing the yearly performance of all stocks, IMAB is one of the better performing stocks in the market, outperforming 98.79% of all stocks.
IMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMAB. While IMAB has a great health rating, there are worries on its profitability.
IMAB Earnings
IMAB Forecast & Estimates
12 analysts have analysed IMAB and the average price target is 8.5 USD. This implies a price increase of 83.58% is expected in the next year compared to the current price of 4.63.
IMAB Groups
Sector & Classification
IMAB Financial Highlights
Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 89.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.22% | ||
| ROE | -19.14% | ||
| Debt/Equity | 0 |
IMAB Ownership
IMAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.645B | ||
| AMGN | AMGEN INC | 15.25 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.68 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.84 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 11.2 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.55 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMAB
Company Profile
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Company Info
IPO: 2020-01-17
I-MAB-SPONSORED ADR
Suite 400, 2440 Research Blvd
Rockville MARYLAND 201210 US
CEO: Joan Huaqiong Shen
Employees: 32
Phone: 13016702800
I-MAB-SPONSORED ADR / IMAB FAQ
What does IMAB do?
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
What is the current price of IMAB stock?
The current stock price of IMAB is 4.63 USD. The price decreased by -0.22% in the last trading session.
Does IMAB stock pay dividends?
IMAB does not pay a dividend.
How is the ChartMill rating for I-MAB-SPONSORED ADR?
IMAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for IMAB stock?
12 analysts have analysed IMAB and the average price target is 8.5 USD. This implies a price increase of 83.58% is expected in the next year compared to the current price of 4.63.
Is I-MAB-SPONSORED ADR (IMAB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMAB.
What is the ownership structure of I-MAB-SPONSORED ADR (IMAB)?
You can find the ownership structure of I-MAB-SPONSORED ADR (IMAB) on the Ownership tab.